Literature DB >> 18319601

Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.

M Augustin1, K Krüger, M A Radtke, I Schwippl, K Reich.   

Abstract

BACKGROUND: Plaque-type psoriasis produces significant morbidity, has negative effects on patients' health-related quality of life (HRQoL), and represents an economic burden.
OBJECTIVES: The assessment of disease severity, HRQoL and health care in plaque-type psoriasis in everyday German medical practice.
METHODS: Details of patients with plaque-type psoriasis were recorded by 48 dermatologists in Germany. During the visit, demographic data, medical history, previous and current treatments, occupational impairment, the current state of the disease (measured by the Psoriasis Area and Severity Index; PASI), overall lesion severity, and HRQoL were evaluated.
RESULTS: In total, 1,511 plaque-type psoriasis patients were included. The average PASI score was 12.0. The average Dermatology Life Quality Index score was 8.6. Among the patients with the severest psoriasis (PASI >20), only 45.4% had ever been prescribed systemic treatments.
CONCLUSIONS: Psoriasis patients have a reduced HRQoL and are not sufficiently treated in practice. A more widespread use of systemic treatment and the definition of treatment goals are essential to improve the standard of care for psoriasis patients. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18319601     DOI: 10.1159/000119415

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  36 in total

1.  Ustekinumab.

Authors:  Kristian Reich; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

Review 2.  Psoriasis--new insights into pathogenesis and treatment.

Authors:  Ulrich Mrowietz; Kristian Reich
Journal:  Dtsch Arztebl Int       Date:  2009-01-05       Impact factor: 5.594

Review 3.  [Health services research in dermatology. Current status].

Authors:  N Franzke; M Augustin
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

4.  Cost-of-illness of chronic leg ulcers in Germany.

Authors:  Sandra Purwins; Katharina Herberger; Eike Sebastian Debus; Stephan J Rustenbach; Peter Pelzer; Eberhard Rabe; Elmar Schäfer; Rudolf Stadler; Matthias Augustin
Journal:  Int Wound J       Date:  2010-04       Impact factor: 3.315

Review 5.  [Nail psoriasis--an ignored disorder. Pathogenesis, diagnosis and therapy].

Authors:  C Kahl; B Hansen; K Reich
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

Review 6.  Recent advances on the roles of epidermal growth factor receptor in psoriasis.

Authors:  Sijia Wang; Zhuoli Zhang; Han Peng; Kang Zeng
Journal:  Am J Transl Res       Date:  2019-02-15       Impact factor: 4.060

7.  Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice.

Authors:  Hiroki Mori; Kojo Arita; Takayuki Yamaguchi; Midori Hirai; Yoichi Kurebayashi
Journal:  Kobe J Med Sci       Date:  2016-09-09

8.  Perceived health is partially associated with the symptomatological profile in patients with benign and severe conditions: the case of congenital heart disease.

Authors:  D Schoormans; M A G Sprangers; W Budts; B J M Mulder; S Apers; P Moons
Journal:  Qual Life Res       Date:  2012-07-31       Impact factor: 4.147

9.  [Health care of chronic inflammatory skin diseases : Do affected individuals seek dermatological care?]

Authors:  M C Schielein; L Tizek; F Seifert; T Biedermann; A Zink
Journal:  Hautarzt       Date:  2019-11       Impact factor: 0.751

10.  Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial.

Authors:  M Augustin; S Abeysinghe; U Mallya; A Qureshi; N Roskell; D McBride; C Papavassillis; J Gelfand
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-12-10       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.